Immunosuppressors and reversion of multidrug-resistance

Critical Reviews in Oncology/Hematology

Volumn 56, Issue 1 SPEC. ISS., 2005, Pages 61-70

  Aouali, Nassera ^a   Eddabra, Lahcen ^b   Macadré, Jérôme ^b   Morjani, Hamid ^b,c,d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^c JE2428 Onco Pharmacology Group   (France)

^d American Association for Cancer Research   (United States)

Author keywords

Immunosuppressors; Multidrug resistance; Reversion

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE; BIRICODAR; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GEMCITABINE; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PIRARUBICIN; PROBENECID; QUINIDINE; QUININE; TAMOXIFEN; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZOSUQUIDAR;

APOPTOSIS; CANCER; CANCER SURVIVAL; CANCER THERAPY; CELL DEATH; CLINICAL TRIAL; DOSE RESPONSE; DRUG POTENCY; DRUG RESISTANCE; GLYCOSYLATION; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; PHENOTYPE; PROTEIN FUNCTION; REVIEW; SYNTHESIS;

EID: 24644501249     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.12.010     Document Type: Review

References (110)

1. M.M. Gottesman How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture Cancer Res 53 1993 747 754
2. M. Volm, M. Kastel, J. Mattern, and T. Efferth Expression of resistance factors (P-glycoprotein, glutathione S-transferase-π, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas Cancer 71 1993 3981 3987
3. K. Nooter, and G. Stoter Molecular mechanisms of multidrug resistance in cancer chemotherapy Pathol Res Pract 192 1996 768 780
4. E. Friche, M.K. Danks, C.A. Schmidt, and W.T. Beck Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells Cancer Res 51 1991 4213 4218
5. M.I. Tiirikainen, E. Elonen, M.T. Syrjala, S.E. Jansson, and T. Krusius Flow cytometric analysis of glutathione-S-transferase-pi in acute leukemia Leukemia 8 1994 978 984
6. R.L. Juliano, and V. Ling A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biophys Biochim Acta 455 1976 152 162
7. S.P. Cole, G. Bhardwaj, and J.H. Gerlach Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1992 1650 1654
8. I. Leier, G. Jedlitschky, U. Buchholz, S.P.C. Cole, R.G. Deeley, and D. Keppler The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates J Biol Chem 269 1994 27807 27810
9. P. Borst, R. Evers, M. Kool, and J. Wijnholds The multidrug resistance protein family Biochim Biophys Acta 1461 1999 347 357
10. L.A. Doyle, W. Yang, and L.V. Abruzzo A multidrug resistance transporter from human MCF-7 breast cancer cells Proc Natl Acad Sci USA 95 1998 15665 15670
11. T. Litman, T.E. Druley, W.D. Stein, and S.E. Bates From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance Cell Mol Life Sci 58 2001 931 959
12. Y. Honjo, C.A. Hrycyna, and Q.W. Yan Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells Cancer Res 61 2001 6635 6639
13. J.H. Burchenal, E. Robinson, and S.F. Johnston The induction of resistance to 4-amino-N10-methyl-pteroylglutaminic acid in a strain of transmitted mouse leukemia Science 111 1950 116 117
14. K. Dano Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells Biochim Biophys Acta 323 1973 466 483
15. K. Ueda, D.P. Clark, and C.J. Chen The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation J Biol Chem 262 1987 505 508
16. J.R. Riordan, and V. Ling Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability J Biol Chem 254 1979 12701 12705
17. J.F. Riou, A. Naudin, and F. Lavelle Effects of Taxotere on rnurine and human tumor cell lines Biochem Biophys Res Commun 87 August (1) 1992 164 170
18. L.M. Greenberger, L. Lothstein, S.S. Williams, and S.B. Horwitz Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines Proc Natl Acad Sci USA 85 1988 3762 3766
19. R.F. Ozols, R.E. Cunnion, and R.W. Klecker Jr. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients J Clin Oncol 5 1987 641 647
20. W.S. Dalton, T.M. Grogan, and P.S. Meltzer Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy J Clin Oncol 7 1989 1578 1579
21. S.E. Salmon, W.S. Dalton, and T.M. Grogan Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer Blood 78 1991 44 50
22. G.C. Wishart, D. Bissett, and J. Paul Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial J Clin Oncol 12 1994 1771 1777
23. E. Solary, B. Witz, and D. Caillot Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study Blood 88 August (4) 1996 1198 1205
24. S. Bennis, F. Ichas, and J. Robert Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line Int J Cancer 62 1995 283 290
25. R. Belhoussine, H. Morjani, R. Lahlil, and M. Manfait Evidence for reversal of multidrug resistance by quinine in LR73 cells without alteration of nuclear pirarubicin uptake and down-regulation of mdrl gene, expression Int J Cancer 73 1997 600 606
26. U.A. Germann, D. Shlyakhter, and V.S. Mason Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro Anticancer Drugs 8 1997 125 140
27. U.A. Germann, P.J. Ford, D. Shlyakhter, V.S. Mason, and M.W. Harding Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP Anticancer Drugs 8 1997 141 155
28. R.A. Peck, J. Hewett, and M.W. Harding Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin J Clin Oncol 19 2001 3130 3141
29. A. Pierre, T.A. Dunn, and L. Kraus-Berthier In vitro and in vivo circumvention of multidrug resistance by Sender 9788, a novel triazinoaminopiperidine derivative Invest New Drugs 10 1992 137 148
30. C.J. Punt, E.E. Voest, and E. Tueni Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer Br J Cancer 76 1997 1376 1381
31. A.H. Dantzig, K.L. Law, J. Cao, and J.J. Starling Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic Curr Med Chem 8 2001 39 50
32. E.H. Rubin, D.P. de Alwis, and I. Pouliquen A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies Clin Cancer Res 8 2002 3710 3717
33. J. Robert, and C. Jarry Multidrug resistance reversal agents J Med Chem 46 2003 4805 4817
34. T. Saeki, K. Ueda, Y. Tanigawara, R. Hori, and T. Komano Human P-glycoprotein transports cyclosporin A and FK506 J Biol Chem 268 1993 6077 6080
35. A. Shirai, M. Naito, and T. Tatsuta Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein Biochim Biophys Acta 1222 1994 400 404
36. U. Schramm, G. Fricker, R. Wenger, and D.S. Miller P-glycoprotein- mediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules Am J Physiol 268 1995 F46 F52
37. W.D. Stein Kinetics of the multidrug transporter (P-glycoprotein) and its reversal Physiol Rev 77 1997 545 590
38. T. Litman, T. Zeuthen, T. Skovsgaard, and W.D. Stein Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity Biochim Biophys Acta 1361 1997 159 168
39. J.L. Merlin, A. Guerci, and S. Marchal Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies Blood 84 1994 262 269
40. J.L. Merlin, A.P. Guerci, and S. Marchal Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia Br J Haematol 103 1998 480 487
41. O. Legrand, G. Simonin, J.Y. Perrot, R. Zittoun, and J.P. Marie Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients Blood 91 1998 4480 4488
42. O. Legrand, G. Simonin, A. Beauchamp-Nicoud, R. Zittoun, and J.P. Marie Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia Blood 94 1998 1046 1056
43. P. Sonneveld, B.G. Durie, and H.M. Lokhorst Modulation of multidrug-resistant multiple myeloma by cyclosporine. The Leukaemia Group of the EORTC and the HO VON Lancet 340 1992 255 259
44. A.F. List, C. Spier, and J. Greer Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia J Clin Oncol 11 1993 1652 1660
45. P. Sonneveld, S. Suciu, and P. Weijermans Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD)compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase HI study (06914) Br J Haematol 115 2001 895 902
46. A.F. List, K.J. Kopecky, and C.L. Willman Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study Blood 98 2001 3212 3220
47. P.R. Twentyman Cyclosporins as drug resistance modifiers Biochem Pharmacol 43 1992 109 117
48. P.R. Twentyman, and N.M. Bleehen Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin Eur J Cancer 27 1991 1639 1642
49. D. Boesch, C. Gaveriaux, B. Jachez, A. Pourtier-Manzanedo, P. Bollinger, and F. Loor In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833 Cancer Res 51 1991 4226 4233
50. D.J. Boote, I.F. Dennis, and P.R. Twentyman Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer J Clin Oncol 14 1996 610 618
51. G. Giaccone, S.C. Linn, and J. Welink A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors Clin Cancer Res 3 1997 2005 2015
52. R. Advani, H.I. Saba, and M.S. Tallman Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar) Blood 93 1999 787 795
53. P.M. Fracasso, P. Westervelt, and C.L. Fears Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies J Clin Oncol 18 2000 1124 1134
54. G.D. Leonard, T. Fojo, and S.E. Bates The role of ABC transporters in clinical practice Oncologist 8 2003 411 424
55. S.E. Bates Solving the problems of multidrug-resistance: ABC transporters in clinical oncology I.B. Holland S.P. Cole K. Kuchler ABC proteins: from bacteria to man 2002 Elsevier Science London 359 391
56. L. Beketic-Oreskovic, G.E. Duran, G. Chen, C. Dumontet, and B.I. Sikic Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdrl gene activation by the cyclosporin PSC 833 J Natl Cancer Inst 87 1995 1593 1602
57. H.A. Cocker, N. Tiffin, K. Pritchard-Jones, C.R. Pinkerton, and L.R. Kelland In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line Clin Cancer Res 7 2001 3193 3198
58. T. Levade, and J.P. Jaffrezou Signalling sphingomyelinases: which, where, how and why? Biochim Biophys Acta 1438 1999 1 17
59. H. Sietsma, R.J. Veldman, and J.W. Kok The involvement of sphingolipids in multidrug resistance J Membr Biol 181 2001 153 162
60. D.K. Perry The role of de novo ceramide synthesis in chemotherapy-induced apoptosis Ann N Y Acad Sci 905 2000 91 96
61. E.C. Mandon, I. Ehses, J. Rother, G. van Echten, and K. Sandhoff Subcellular localization and membrane topology of serine palmitoyltransferase, 3-dehydrosphinganine reductase, and sphinganine N-acyltransferase in mouse liver J Biol Chem 267 1992 11144 11148
62. C. Michel, and G. van Echten-Deckert Conversion of dihydroceramide to ceramide occurs at the cytosolic face of the endoplasmic reticulum FEBS Lett 416 1997 153 155
63. Y.A. Hannun, C. Luberto, and K.M. Argraves Enzymes of sphingolipid metabolism: from modular to integrative signaling Biochemistry 40 2001 4893 4903
64. C. Michel, G. van Echten-Deckert, J. Rother, K. Sandhoff, E. Wang, and A.H. Merrill Jr. Characterization of ceramide synthesis. A dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide J Biol Chem 272 1997 22432 22437
65. R. Bose, M. Verheij, A. Haimovitz-Friedman, K. Scotto, Z. Fuks, and R. Kolesnick Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals Cell 82 1995 405 414
66. K.J. Turnbull, B.L. Brown, and P.R. Dobson Caspase-3-like activity is necessary but not sufficient for daunorubicin-induced apoptosis in Jurkat human lymphoblastic leukemia cells Leukemia 13 1999 1056 1061
67. J. Zhang, N. Alter, J.C. Reed, C. Borner, L.M. Obeid, and Y.A. Hannun Bcl-2 interrupts the ceramide-mediated pathway of cell death Proc Natl Acad Sci USA 93 1996 5325 5328
68. R.S. Olshefski, and S. Ladisch Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity Int J Cancer 93 2001 131 138
69. M.C. Cabot, A.E. Giuliano, T.Y. Han, and Y.Y. Liu SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells Cancer Res 59 1999 880 885
70. D. Myrick, D. Blackinton, and J. Klostergaard Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide Leuk Res 23 1999 569 578
71. S. Mehta, D. Blackinton, and I. Omar Combined cytotoxic action of paclitaxel and ceramide against the human Tul38 head and neck squamous carcinoma cell line Cancer Chemother Pharmacol 46 2000 85 92
72. A.D. Tepper, E. de Vries, W.J. van Blitterswijk, and J. Borst Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis J Clin Invest 103 1999 971 978
73. D.K. Perry, J. Carton, A.K. Shah, F. Meredith, D.J. Uhlinger, and Y.A. Hannun Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis J Biol Chem 275 2000 9078 9084
74. N.S. Radin The development of aggressive cancer: a possible role for sphingolipids Cancer Invest 20 2002 779 786
75. A. Suzuki, M. Iwasaki, M. Kato, and N. Wagai Sequential operation of ceramide synthesis and ICE cascade in CPT-11-initiated apoptotic death signaling Exp Cell Res 233 1997 41 47
76. D. Chauvier, H. Morjani, and M. Manfait Ceramide involvement in homocamptothecin- and camptothecin-induced cytotoxicity and apoptosis in colon HT29 cells Int J Oncol 20 2002 855 863
77. Y. Akao, S. Kusakabe, and Y. Banno Ceramide accumulation is independent of camptothecin-induced apoptosis in prostate cancer LNCaP cells Biochem Biophys Res Commun 294 2002 363 370
78. T. Herget, C. Esdar, and S.A. Oehrlein Production of ceramides causes apoptosis during early neural differentiation in vitro J Biol Chem 275 2000 30344 30354
79. B.J. Maurer, L.S. Metelitsa, R.C. Seeger, M.C. Cabot, and C.P. Reynolds Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines J Natl Cancer Inst 91 1999 1138 1146
80. H. Wang, A.G. Charles, A.J. Frankel, and M.C. Cabot Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells Urology 61 2003 1047 1052
81. C.P. Reynolds, B.J. Maurer, and R.N. Kolesnick Ceramide synthesis and metabolism as a target for cancer therapy Cancer Lett 206 2004 169 180
82. C.E. Chalfant, K. Rathman, and R.L. Pinkerman De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1 J Biol Chem 277 2002 12587 12595
83. T. Gomez Del Pulgar, M.L. De Ceballos, M. Guzman, and G. Veiasco Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway J Biol Chem 277 2002 36527 36533
84. T. Gomez del Pulgar, G. Veiasco, C. Sanchez, A. Haro, and M. Guzman De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis Biochem J 363 2002 183 188
85. M.C. Cabot, T.Y. Han, and A.E. Giuliano The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation FEBS Lett 431 1998 185 188
86. C.W. Goulding, A.E. Giuliano, and M.C. Cabot SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein Cancer Lett 149 2000 143 151
87. A. Senchenkov, D.A. Litvak, and M.C. Cabot Targeting ceramide metabolism - a strategy for overcoming drug resistance J Natl Cancer Inst 93 2001 347 357
88. A. Lucci, T.Y. Han, Y.Y. Liu, A.E. Giuliano, and M.C. Cabot Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells Cancer 86 1999 300 311
89. A. Lucci, T.Y. Han, Y.Y. Liu, A.E. Giuliano, and M.C. Cabot Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics Int J Oncol 15 1999 541 546
90. H. Wang, A.E. Giuliano, and M.C. Cabot Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells Mol Cancer Ther 1 2002 719 726
91. C.M. Linardic, and Y.A. Hannun Identification of a distinct pool of sphingomyelin involved in the sphingomyelin cycle J Biol Chem 269 1994 23530 23537
92. C. Bezombes, N. Maestre, G. Laurent, T. Levade, A. Bettaieb, and J.P. Jaffrezou Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KGla cells by the P-glycoprotein blocker PSC833 FASEB J 12 1998 101 109
93. R.H. Peterson, M.B. Meyers, B.A. Spengler, and J.L. Biedler Alteration of plasma membrane glycopeptides and gangliosides of Chinese hamster cells accompanying development of resistance to daunorubicin and vincristine Cancer Res 43 1983 222 228
94. Y. Lavie, H. Cao, S.L. Bursten, A.E. Giuliano, and M.C. Cabot Accumulation of glucosylceramides in multidrug-resistant cancer cells J Biol Chem 271 1996 19530 19536
95. Y.Y. Liu, T.Y. Han, A.E. Giuliano, and M.C. Cabot Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells J Biol Chem 274 1999 1140 1146
96. H. Morjani, N. Aouali, R. Belhoussine, R.J. Veldman, T. Levade, and M. Manfait Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets Int J Cancer 94 2001 157 165
97. J.W. Kok, R.J. Veldman, K. Klappe, H. Koning, C.M. Filipeanu, and M. Muller Differential expression of sphingolipids in MRP1 overexpressing HT29 cells Int J Cancer 87 2000 172 178
98. A. Lucci, W.I. Cho, T.Y. Han, A.E. Giuliano, D.L. Morton, and M.C. Cabot Glucosylceramide: a marker for multiple-drug resistant cancers Anticancer Res 18 1998 475 480
99. R.J. Veldman, K. Klappe, and J. Hinrichs Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus FASEB J 16 2002 1111 1113
100. Y.Y. Liu, T.Y. Han, A.E. Giuliano, and M.C. Cabot Ceramide glycosylation potentiates cellular multidrug resistance FASEB J 15 2001 719 730
101. Y.Y. Liu, T.Y. Han, A.E. Giuliano, N. Hansen, and M.C. Cabot Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance J Biol Chem 275 2000 7138 7143
102. R.J. Veldman, A. Mita, and O. Cuvillier The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs FASEB J 17 2003 1144 1146
103. Y. Lavie, H. Cao, and A. Volner Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells J Biol Chem 272 1997 1682 1687
104. A. Lucci, A.E. Giuliano, and T.Y. Han Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells Int J Oncol 15 1999 535 540
105. K.M. Nicholson, D.M. Quinn, G.L. Kellett, and J.R. Warr Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase Br J Cancer 81 1999 423 430
106. E. Coezy, J.L. Borgna, and H. Rochefort Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth Cancer Res 42 1982 317 323
107. M.C. Cabot, A.E. Giuliano, A. Volner, and T.Y. Han Tamoxifen retards glycosphingolipid metabolism in human cancer cells FEBS Lett 394 1996 129 131
108. E. Pommerenke, J. Mattern, and M. Volm Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo J Cancer Res Clin Oncol 120 1994 422 426
109. G. Szakacs, J.P. Annereau, and S. Lababidi Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells Cancer Cell 6 2004 129 137
110. G. Lehne, D.R. Sorensen, and G.E. Tjonnfjord The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice Leukemia 16 2002 2388 2394